Ocumension Therapeutics (HKSE:01477) FCF Yield % : -12.35 (As of Jun. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Ocumension Therapeutics's Trailing 12-Month Free Cash Flow is HK$-590.4 Mil, and Market Cap is HK$4,779.3 Mil. Therefore, Ocumension Therapeutics's FCF Yield % for today is -12.35%.

The historical rank and industry rank for Ocumension Therapeutics's FCF Yield % or its related term are showing as below:

HKSE:01477' s FCF Yield % Range Over the Past 10 Years
Min: -22.81 Med: -11.94 Max: -6.71
Current: -12.35

During the past 6 years, the highest FCF Yield % of Ocumension Therapeutics was -6.71%. The lowest was -22.81%. And the median was -11.94%.

HKSE:01477's FCF Yield % is ranked better than
53.19% of 1553 companies
in the Biotechnology industry
Industry Median: -14.22 vs HKSE:01477: -12.35

Ocumension Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -170.05%.

Ocumension Therapeutics FCF Yield % Historical Data

The historical data trend for Ocumension Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics FCF Yield % Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-3.86

-9.04

-8.44

-12.79

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial						-10.37	-5.65	-9.41	-12.35	-11.50

Competitive Comparison of Ocumension Therapeutics's FCF Yield %

For the Biotechnology subindustry, Ocumension Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocumension Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's FCF Yield % falls into.

Ocumension Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Ocumension Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-590.415	/	4615.23872
	=	-12.79%

Ocumension Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-265.366	*	2	/	4615.23872
	=	-11.50%

Ocumension Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Ocumension Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Liu Ye	2101 Beneficial owner
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Chen Ziqing	2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p.	2101 Beneficial owner
Boyu Capital Fund Iv, L.p	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines